“Global Pre-Filled Syringes market set to grow to $19bn by 2024” says new Visiongain report

31 January 2019
Pharma

Visiongain has launched a new pharma report Global Pre-Filled Syringes Market Forecast 2019-2029: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes, Pen Injectors and Autoinjectors, Insulin Therapies, Rheumatoid Arthritis (RA) Therapies, Growth Hormones, Vaccines, PCSK9 Inhibitors.

The pre-filled syringes market has become more competitive in recent years as both syringe component suppliers and pharma companies develop product offerings to compete with established device makers. Rapid growth in this market will be due to the increasing burden of chronic disease, the launch of new biological drugs and biosimilars and pharma companies’ need for more complex drug delivery solutions including innovative pen injectors and autoinjectors.

The lead analyst of the report commented "The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.

Innovation, suitability for use with viscous and higher-volume drugs and designing products with usability in mind will help manufacturers in this market to differentiate their products and gain market share in an increasingly competitive environment."

Leading companies featured in the report include BD, Gerresheimer, Schott, SHL Group, Ypsomed and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever